Abstract:Abstract Homologous recombination (HR) repair deficiency impairs the proper maintenance of genomic stability, thus rendering cancer cells vulnerable to loss or inhibition of DNA repair proteins, such as poly(ADP-ribose) polymerase-1 (PARP-1). Inhibitors of nuclear PARPs are effective therapeutics for a number of different types of cancers. Here we review key concepts and current progress on the therapeutic use of PARP inhibitors (PARPi). PARPi selectively induce synthetic lethality in cancer cells with homologous recombination deficiencies (HRDs), the most notable being cancer cells harboring mutations in the BRCA1 and BRCA2 genes. Recent clinical evidence, however, shows that PARPi can be effective as cancer therapeutics regardless of BRCA1/2 or HRD status, suggesting that a broader population of patients might benefit from PARPi therapy. Currently, four PARPi have been approved by the Food and Drug Administration (FDA) for the treatment of advanced ovarian and breast cancer with deleterious BRCA mutations. Although PARPi have been shown to improve progression-free survival, cancer cells inevitably develop resistance, which poses a significant obstacle to the prolonged use of PARP inhibitors. For example, somatic BRCA1/2 reversion mutations are often identified in patients with BRCA1/2 -mutated cancers after treatment with platinum-based therapy, causing restoration of HR capacity and thus conferring PARPi resistance. Accordingly, PARPi have been studied in combination with other targeted therapies to overcome PARPi resistance, enhance PARPi efficacy, and sensitize tumors to PARP inhibition. Moreover, multiple clinical trials are now actively underway to evaluate novel combinations of PARPi with other anticancer therapies for the treatment of PARPi-resistant cancer. In this review, we highlight the mechanisms of action of PARP inhibitors with or without BRCA1/2 defects and provide an overview of the ongoing clinical trials of PARPi. We also review the current progress on PARPi-based combination strategies and PARP inhibitor resistance.

Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors

PARP inhibitor resistance: the underlying mechanisms and clinical implications

Advances and Perspectives of PARP Inhibitors

PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance

Molecular mechanism of PARP inhibitor resistance

The recent advance and prospect of poly(ADP-ribose) polymerase inhibitors for the treatment of cancer

Advances in research of PARP inhibitors in combination with chemotherapeutic agents in the treatment of malignant tumors

Recent Advancements In Parp Inhibitors-Based Targeted Cancer Therapy

Combating Tumor PARP Inhibitor Resistance: Combination Treatments, Nanotechnology, and Other Potential Strategies

Molecular Pathways: Targeting PARP in Cancer Treatment

Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer

Facing Inevitable PARPis Resistance: Mechanisms and Therapeutic Strategies for Breast Cancer Treatment

Prospects for Combining Immune Checkpoint Blockade with PARP Inhibition

Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment

Mechanism of Action of PARP Inhibitors

Understanding and overcoming resistance to PARP inhibitors in cancer therapy

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications

The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment